202 related articles for article (PubMed ID: 8610630)
21. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer.
Quilty PM; Kirk D; Bolger JJ; Dearnaley DP; Lewington VJ; Mason MD; Reed NS; Russell JM; Yardley J
Radiother Oncol; 1994 Apr; 31(1):33-40. PubMed ID: 7518932
[TBL] [Abstract][Full Text] [Related]
22. [Use of strontium-89 in the analgesic treatment of cancer patients with bone metastases].
Baranauskas Z; Valuckas K; Aleknavicius E; Jankevicius F; Burneckis A; Paviloniene I
Medicina (Kaunas); 2006; 42(1):11-4. PubMed ID: 16467608
[TBL] [Abstract][Full Text] [Related]
23. Radionuclide therapy of cancer patients with bone metastases.
Yaneva MP; Semerdjieva M; Radev LR; Ivanova EK; Geiman M; Vlaikova MI; Mihova LS
Folia Med (Plovdiv); 2005; 47(3-4):63-9. PubMed ID: 16761397
[TBL] [Abstract][Full Text] [Related]
24. Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain.
Berna L; Carrio I; Alonso C; Ferré J; Estorch M; Torres G
Eur J Nucl Med; 1995 Oct; 22(10):1101-4. PubMed ID: 8542891
[TBL] [Abstract][Full Text] [Related]
25. Strontium chloride Sr 89 for treating pain from metastatic bone disease.
Nightengale B; Brune M; Blizzard SP; Ashley-Johnson M; Slan S
Am J Health Syst Pharm; 1995 Oct; 52(20):2189-95. PubMed ID: 8564588
[TBL] [Abstract][Full Text] [Related]
26. [Bone metastases treated with radiopharmaceuticals].
Giammarile F
Bull Cancer; 2013 Nov; 100(11):1223-7. PubMed ID: 24409472
[TBL] [Abstract][Full Text] [Related]
27. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.
Dafermou A; Colamussi P; Giganti M; Cittanti C; Bestagno M; Piffanelli A
Eur J Nucl Med; 2001 Jul; 28(7):788-98. PubMed ID: 11504074
[TBL] [Abstract][Full Text] [Related]
28. Hematologic depression following therapy with strontium-89 chloride.
Cowan RJ; Chilton HM; Cooper MR; Ferree CR; Watson EE; Robinson RG
Clin Nucl Med; 1986 Dec; 11(12):845-6. PubMed ID: 2434277
[TBL] [Abstract][Full Text] [Related]
29. Clinical experience with strontium-89 in prostatic and breast cancer patients.
Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
[TBL] [Abstract][Full Text] [Related]
30. Strontium 89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience.
Ashayeri E; Omogbehin A; Sridhar R; Shankar RA
J Natl Med Assoc; 2002 Aug; 94(8):706-11. PubMed ID: 12152927
[TBL] [Abstract][Full Text] [Related]
31. Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience.
Windsor PM
Clin Oncol (R Coll Radiol); 2001; 13(3):219-27. PubMed ID: 11527299
[TBL] [Abstract][Full Text] [Related]
32. Strontium-89 (Sr-89) chloride in the treatment of various cancer patients with multiple bone metastases.
Zenda S; Nakagami Y; Toshima M; Arahira S; Kawashima M; Matsumoto Y; Kinoshita H; Satake M; Akimoto T
Int J Clin Oncol; 2014 Aug; 19(4):739-43. PubMed ID: 23877652
[TBL] [Abstract][Full Text] [Related]
33. A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone.
McEwan AJ; Amyotte GA; McGowan DG; MacGillivray JA; Porter AT
Nucl Med Commun; 1994 Jul; 15(7):499-504. PubMed ID: 7970425
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
Liepe K; Franke WG; Kropp J; Koch R; Runge R; Hliscs R
Nuklearmedizin; 2000 Sep; 39(6):146-51. PubMed ID: 11057405
[TBL] [Abstract][Full Text] [Related]
35. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy.
Tu SM; Kim J; Pagliaro LC; Vakar-Lopez F; Wong FC; Wen S; General R; Podoloff DA; Lin SH; Logothetis CJ
J Clin Oncol; 2005 Nov; 23(31):7904-10. PubMed ID: 16258090
[TBL] [Abstract][Full Text] [Related]
36. [A strontium-89 injection: a simple treatment of painful bone metastases in patients with prostate cancer unresponsive to hormonal treatment].
Jager PL; Mensink HJ; van den Bergh AC; Piers DA
Ned Tijdschr Geneeskd; 1999 May; 143(19):969-73. PubMed ID: 10368715
[TBL] [Abstract][Full Text] [Related]
37. [Internal strontium-89 radiotherapy for malignant bony metastasis].
Lou C; Zhang D; Yu L
Zhonghua Zhong Liu Za Zhi; 2001 Nov; 23(6):507-9. PubMed ID: 11859724
[TBL] [Abstract][Full Text] [Related]
38. [The role of systemic radiotherapy in the combined treatment for hormone-resistant prostate cancer].
Solodky VA; Pavlov AY; Panshin GA; Gafanov RA; Fastovets SV; Isaev TK
Vopr Onkol; 2015; 61(1):31-3. PubMed ID: 26016142
[TBL] [Abstract][Full Text] [Related]
39. Strontium and samarium therapy for bone metastases from prostate carcinoma.
Dickie GJ; Macfarlane D
Australas Radiol; 1999 Nov; 43(4):476-9. PubMed ID: 10901963
[TBL] [Abstract][Full Text] [Related]
40. [Strontium chloride (89Sr-chloride) fractional injection method for bone metastases treatment].
Fomin DK; Smirnov IuN; Tararukhina OB; Nazarov AA
Vopr Onkol; 2012; 58(1):116-8. PubMed ID: 22629840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
